ERBB2 and breast carcinoma: In line with these observations, evidence of ALT is observed in a subset (∼15%) of HER2-enriched breast cancer patients who presented with lymph node metastases at the time of initial diagnosis and ultimately succumbed to highly aggressive disease (Subhawong et al, 2009).